Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain

To examine the distributions of VIP/PACAP receptors (VPAC1, VPAC2, and PAC1 receptors) in the brain and to identify the cell types that express these receptors, we performed immunohistochemistry and double immunofluorescence in the rat brain with specific antibodies. The immunohistochemistry revealed that the receptors had distinctive, complementary, and overlapping distribution patterns. High levels of the VPAC1 receptor were expressed in the cerebral cortex, hippocampal formation, deep cerebellar nuclei, thalamus, hypothalamus, and brainstem. The VPAC2 receptors were concentrated in the cerebral cortex, hippocampal formation, amygdalar regions, cerebellar cortex, deep cerebellar nuclei, hypothalamus, and brainstem. On the other hand, the PAC1 receptors had a more restricted distribution pattern in the brain, and high levels of the PAC1 receptors were confined to the cerebellar cortex, deep cerebellar nuclei, epithalamus, hypothalamus, brainstem, and white matter of many brain regions. Also, many fibers expressing the PAC1 receptors were observed in various areas, i.e., the thalamus, hypothalamus, and brainstem. The double immunofluorescence showed that the VIP/PACAP receptors were confined to the neuroglia as well as the neurons. All three types of the VIP/PACAP receptors were expressed in the astrocytes, and the PAC1 receptors were also expressed in the oligodendrocytes. These findings indicate that VIP and PACAP exert their functions through their receptors in specific locations in different combinations. We hope that this first demonstration of the distributions of the VIP/PACAP receptors provides data useful in the investigation of the mechanisms of the many functions of VIP and PACAP in the brain, which require further elucidation. J. Comp. Neurol. 476:388–413, 2004. © 2004 Wiley‐Liss, Inc.

[1]  P. Gressens,et al.  VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells , 2004, The European journal of neuroscience.

[2]  N. Mizuno,et al.  Substance P-, vasoactive intestinal polypeptide-, and cholecystokinin-like immunoreactive fiber projections from the superior colliculus to the dorsal lateral geniculate nucleus in the rat , 2004, Experimental Brain Research.

[3]  Sang-Hun Lee,et al.  Vasoactive intestinal peptide selectively depolarizes thalamic relay neurons and attenuates intrathalamic rhythmic activity. , 2003, Journal of neurophysiology.

[4]  H. Vaudry,et al.  Pituitary adenylate cyclase‐activating polypeptide prevents C2‐ceramide‐induced apoptosis of cerebellar granule cells , 2003, Journal of neuroscience research.

[5]  D. Prince,et al.  Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase-Activating Polypeptide Activate Hyperpolarization-Activated Cationic Current and Depolarize Thalamocortical Neurons In Vitro , 2003, The Journal of Neuroscience.

[6]  H. Vaudry,et al.  Pituitary adenylate cyclase‐activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA‐dependent mechanism , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide Prevents C 2-Ceramide-Induced Apoptosis of Cerebellar Granule Cells , 2003 .

[8]  J. Hannibal Pituitary adenylate cyclase‐activating peptide in the rat central nervous system: An immunohistochemical and in situ hybridization study , 2002, The Journal of comparative neurology.

[9]  Jie Liu,et al.  Local administration of vasoactive intestinal peptide after nerve transection accelerates early myelination and growth of regenerating axons , 2002, Journal of the peripheral nervous system : JPNS.

[10]  E. Maywood,et al.  The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei , 2002, Cell.

[11]  H. Vaudry,et al.  PACAP protects cerebellar granule neurons against oxidative stress‐induced apoptosis , 2002, The European journal of neuroscience.

[12]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kim,et al.  Age-related changes in the distribution of nitrotyrosine in the cerebral cortex and hippocampus of rats , 2002, Brain Research.

[14]  F. Jirik,et al.  Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism. , 2001, Molecular endocrinology.

[15]  M. Brunelli,et al.  Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region. , 2001, Learning & memory.

[16]  F. Mcmorris,et al.  Agonists calcitonin, corticotropin‐releasing hormone, and vasoactive intestinal peptide, but not prostaglandins or β‐adrenergic agonists, elevate cyclic adenosine monophosphate levels in oligodendroglial cells , 2001, Journal of neuroscience research.

[17]  F. Jamen,et al.  Dissociation between Light-Induced Phase Shift of the Circadian Rhythm and Clock Gene Expression in Mice Lacking the Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor , 2001, The Journal of Neuroscience.

[18]  P. Zhao,et al.  Pituitary Adenylyl Cyclase-Activating Polypeptide Stimulates DNA Synthesis But Delays Maturation of Oligodendrocyte Progenitors , 2001, The Journal of Neuroscience.

[19]  D. Cutler,et al.  Vasoactive intestinal polypeptide (VIP) phase‐shifts the rat suprachiasmatic nucleus clock in vitro , 2001, The European journal of neuroscience.

[20]  F. Holsboer,et al.  Mild deficits in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks. , 2000, Brain research. Molecular brain research.

[21]  N. Sherwood,et al.  THE ORIGIN AND FUNCTION OF THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/GLUCAGON SUPERFAMILY , 2000 .

[22]  S. Said The Viktor Mutt Memorial Lecture Protection by VIP and Related Peptides Against Cell Death and Tissue Injury , 2000, Annals of the New York Academy of Sciences.

[23]  A Fournier,et al.  Comparative distribution of pituitary adenylate cyclase‐activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development , 2000, The Journal of comparative neurology.

[24]  M. Sofroniew,et al.  Pituitary adenylate cyclase‐activating polypeptide promotes the survival of basal forebrain cholinergic neurons in vitro and in vivo: comparison with effects of nerve growth factor , 2000, The European journal of neuroscience.

[25]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.

[26]  J. Bockaert,et al.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. , 2000, The Journal of clinical investigation.

[27]  E. Melamed,et al.  Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease 1 This manuscript is based on a poster presented at the Brain Research Interactive Symposium on “Neuropeptides at the Millennium”, Miami, October 1999. 1 , 2000, Brain Research.

[28]  I. Gozes,et al.  Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia‐mediated Neurotrophism , 1999, Annals of the New York Academy of Sciences.

[29]  J. Hannibal,et al.  Pituitary adenylyl cyclase-activating peptide: a pivotal modulator of glutamatergic regulation of the suprachiasmatic circadian clock. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Burgunder,et al.  Thalamic reticular nucleus parcellation delineated by VIP and TRH gene expression in the rat , 1999, Journal of Chemical Neuroanatomy.

[31]  H. Vaudry,et al.  Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Cavallaro,et al.  Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes , 1999, The European journal of neuroscience.

[33]  G. Sachs,et al.  The Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor (PAC1‐R) Is Expressed on Gastric ECL Cells: Evidence by Immunocytochemistry and RT‐PCR , 1998, Annals of the New York Academy of Sciences.

[34]  K. Dickman,et al.  Glutamate Toxicity in the Lung and Neuronal Cells: Prevention or Attenuation by VIP and PACAP , 1998, Annals of the New York Academy of Sciences.

[35]  H. Arima,et al.  Anorectic Effect of Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Rats: Lack of Evidence for Involvement of Hypothalamic Neuropeptide Gene Expression , 1998, Journal of neuroendocrinology.

[36]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway , 1998, Neuroscience.

[37]  S. Schiffmann,et al.  Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain , 1997, Peptides.

[38]  I. Gozes,et al.  Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. , 1997, Journal of neurobiology.

[39]  S. Shioda,et al.  Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain , 1997, Neuroscience Research.

[40]  K. Matsumoto,et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. , 1997, Endocrinology.

[41]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts , 1997, Neuroscience.

[42]  Tony Wu,et al.  Vasoactive intestinal polypeptide enhances the GABAergic synaptic transmission in cultured hippocampal neurons , 1997, Brain Research.

[43]  R. V. Sharma,et al.  Molecular Cloning of a Novel Variant of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Receptor That Stimulates Calcium Influx by Activation of L-type Calcium Channels* , 1996, The Journal of Biological Chemistry.

[44]  R. Shigemoto,et al.  Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study , 1996, The Journal of comparative neurology.

[45]  S. Rawlings,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. , 1996, Endocrine reviews.

[46]  I. Gozes,et al.  Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Fischer,et al.  Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats , 1995, Peptides.

[48]  B. Rusak,et al.  Neuropeptides phase shift the mammalian circadian pacemaker , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  A. Harmar,et al.  The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization , 1995, Neuroscience.

[50]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[51]  J. Curlewis,et al.  Effects of Pituitary Adenylate Cyclase‐Activating Polypeptide (PACAP) and Vasoactive Intestinal Polypeptide (VIP) on Prolactin, Luteinizing Hormone and Growth Hormone Secretion in the Ewe , 1994, Journal of neuroendocrinology.

[52]  G. Fink,et al.  Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. , 1994, The Journal of endocrinology.

[53]  T. Harmar,et al.  Multiple receptors for PACAP and VIP. , 1994, Trends in pharmacological sciences.

[54]  T. Koike,et al.  Vasoactive intestinal peptide suppresses neuronal cell death induced by nerve growth factor deprivation in rat sympathetic ganglion cells in vitro , 1994, Neuropeptides.

[55]  G. Fink,et al.  The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.

[56]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[57]  R. Shigemoto,et al.  Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide , 1993, Neuron.

[58]  S. Wank,et al.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[59]  N. Barzilai,et al.  38‐Amino acid form of pituitary adenylate cyclase activating peptide induces process outgrowth in human neuroblastoma cells , 1993, Journal of neuroscience research.

[60]  E. Goetzl,et al.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.

[61]  Larry W. Swanson,et al.  Brain Maps: Structure of the Rat Brain , 1992 .

[62]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[63]  B. Gähwiler,et al.  Vasoactive intestinal polypeptide modulates neuronal excitability in hippocampal slices of the rat , 1992, Neuroscience.

[64]  A. Arimura,et al.  Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. , 1991, Neuroendocrinology.

[65]  S. Lipton,et al.  VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro , 1990, Neuron.

[66]  M. Culler,et al.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.

[67]  M. Tohyama,et al.  The organization of the rat lateral geniculate body by immunohistochemical analysis of neuroactive substances , 1989, Brain Research.

[68]  Karen L. Elkins,et al.  Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide , 1988, Nature.

[69]  W. Rostène,et al.  Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system , 1986, Brain Research.

[70]  N. Tamaki,et al.  Effect of vasoactive intestinal polypeptide on growth hormone secretion in perifused acromegalic pituitary adenoma tissues. , 1982, The Journal of clinical endocrinology and metabolism.

[71]  J. Fahrenkrug,et al.  VIP STIMULATES PROLACTIN RELEASE IN WOMEN , 1981, The Lancet.

[72]  O. K. Langley,et al.  Double labeling immunohistochemical technique provides evidence of the specificity of glial cell markers. , 1979, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[73]  S. Said,et al.  Vasoactive intestinal polypeptide: release into hypophyseal portal blood. , 1979, Life sciences.

[74]  E. C. Christian,et al.  Letter: Primary liver-cell carcinoma in Accra. , 1976, Lancet.

[75]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.